Advanced search
Publication Cover
Risk Management and Healthcare Policy Volume 13, 2020 - Issue
Submit an article Journal homepage
249
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study

Sultan Alghadeeer1 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCorrespondence[email protected]
,
Abdullah A Alzahrani2 King Saud University Medical City, Riyadh, Saudi Arabia
,
Wesal Y Alalayet2 King Saud University Medical City, Riyadh, Saudi Arabia
,
Abdulrahman A Alkharashi2 King Saud University Medical City, Riyadh, Saudi Arabia
&
Mohammed N Alarifi1 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Pages 1175-1179 | Published online: 17 Aug 2020

References

  • Coumadin (warfarin Sodium). Prescribing Information. Princeton (NJ): Bristol-Myers Squibb, Inc.; 2017.
  • Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145:105–12.e15. doi:10.1053/j.gastro.2013.02.04123470618
  • Zheng Y, Sorensen SV, Gonschior A-K, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther. 2014;36(12):2015–28.e2. doi:10.1016/j.clinthera.2014.09.01525438722
  • Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505. doi:10.1136/bmj.k250529973392
  • Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239. doi:10.1055/s-0038-16515878470047
  • Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37–41. doi:10.1016/j.thromres.2008.09.01619062079
  • Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166(5):565–571. doi:10.1001/archinte.166.5.56516534045
  • Canadian Agency for Drugs and Technologies in Health (CADTH). Optimal Warfarin Management for the Prevention of ThromboembolicEvents in Patients with Atrial Fibrillation: A Systematic Review of theClinical Evidence [Internet]. Ottawa (ON): Canada; November, 2011. CADTH 290 Optimal Use Report, No. 1.2A. Available from: https://www.ncbi.nlm.nih.gov/books/NBK169490/. Accessed August 5, 2020.
  • Thrombosis Canada. Warfarin: Management of Out-Of-Range INRs. Whitby, ON: Thrombosis Canada; 2015 Available from: http://thrombosiscanada.ca/clinicalguides/#. Accessed 127, 2010.
  • Shaw J, Harrison J, Harrison JE. Community Pharmacist-Led Anticoagulation Management Service: Final Report. Wellington, New Zealand: Health Workforce New Zealand; Septmeber; 2011.
  • Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e44s–e88s. doi:10.1378/chest.11-229222315269
  • British committee for standards in haematology: guidelines for point of care testing. 2019.
  • Shah KJ, Mansukhani R, Bloomstein D, Serra M. Outcomes of a pharmacist managed anticoagulation service. IOSR J Pharm. 2016;6(10):62–67.
  • Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12(1):88. doi:10.1186/1471-2296-12-8821849052
  • Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ. 2003;169:293–298.12925422
  • Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH. Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. Br J Clin Pharmacol. 2006;62:601–609. doi:10.1111/j.1365-2125.2006.02693.x17061966
  • Marcatto LR, Sacilotto L, Tavares LC, et al. Pharmaceutical care increases time in therapeutic range of patients with poor quality of anticoagulation with warfarin. Front Pharmacol. 2018;9:1052. doi:10.3389/fphar.2018.0105230298004
  • Lee T, Davis E, Kielly J. Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature. Integr Pharm Res Pract. 2016;5:53–63. doi:10.2147/IPRP.S9331229354540
  • Aidit S, Chang Soh Y, Seng Yap C, et al. Effect of standardized warfarin treatment protocol on anticoagulant effect: comparison of a warfarin medication therapy adherence clinic with usual medical care. Front Pharmacol. 2017;8:637. doi:10.3389/fphar.2017.0063729170637
  • Coleman B, Martin C, Barber N, Patterson D. An evaluation of the safety and acceptability of an anticoagulation clinic in a community pharmacy setting - a pilot study. Pharm J. 2004;273:822–824.
  • Ingram SJ, Kirkdale CL, Williams S, et al. Moving anticoagulation initiation and monitoring services into the community: evaluation of the brighton and hove community pharmacy service. BMC Health Serv Res. 2018;18(1):91. doi:10.1186/s12913-018-2901-829415718
  • Thanimalai S, Shafie AA, Hassali MA, Sinnadurai J. Cost-effectiveness of warfarin medication therapy adherence clinic versus usual medical clinic at Kuala Lumpur Hospital. Value Health Reg Issues. 2018;15:34–41.29474176

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.